+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID02880618

Post-Market Registry Evaluating BAROSTIM THERAPY with the CE-Marked BAROSTIM NEO System in Heart Failure with Reduced Ejection Fraction

Led by CVRx, Inc. · Updated on 2026-09-11

500

Participants Needed

30

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people with heart failure who have reduced ejection fraction. This registry study includes subjects recently implanted with the device under approved criteria for heart failure, specifically those with New York Heart Association NYHA functional Class III and left ventricular ejection fraction LVEF of 35% or less despite guideline-directed therapy. The study aims to understand how this therapy performs in a real-world commercial setting. Participants who received the BAROSTIM NEO System within 30 days before enrollment will be followed. Data will be collected from standard care measurements taken before implantation, at enrollment, and then at 3, 6, and 12 months after implantation. The study will track changes in heart failure severity, exercise capacity, heart function, biomarkers, device usage, and healthcare use such as hospitalizations related to heart failure. During the study, participants will undergo evaluations including assessments of their NYHA functional class, six-minute hall walk test, echocardiogram measurements, and blood tests for biomarkers like NT-pro BNP and Troponin HsT. Researchers will monitor hospitalizations over the 12-month follow-up. Each participant will complete the study after 12 months of monitoring following device implantation.

CONDITIONS

Brief Title

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

Research Team

N

Nicole Baumann

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here